An official website of the United States government
Home
Drugs for ATRA (263)
Name
Alternate Names
Aberel
Airol
All-trans-retinoic acid
Avita
Dermairol
Eudyna
Renova
Retin-A
Retinoic acid
Retisol-A
Stieva-A
Vesanoid
Vitamin A Acid
Vitinoin
Abbreviations
ATRA
Vit A
Category
Differentiation inducing agent
Subcategory
None
NSC Number
122758
Primary Site
Histology
None
Remarks
Tretinoin is FDA approved for treatment of acute promyelocytic leukemia (APL). It is a retinoid/differentiation agent and at this time the precise mechanism of action has not been fully elucidated so it cannot be assigned to chemotherapy, hormone or BRM/immunotherapy. Code this agent as treatment in the "Other Therapy" data field (using code 1).
Phase II (head & neck)
Administered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness. Under investigation for treatment of Kaposi sarcoma lesions. FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the "Other Therapy" data field (using code 1).
Phase II (head & neck)
Administered topically, tretinoin stimulates epithelial turnover and reduces epithelial cell cohesiveness. Under investigation for treatment of Kaposi sarcoma lesions. FDA approved therapy of acute promyelocytic leukemia. NCI.Code this agent as treatment in the "Other Therapy" data field (using code 1).
Coding
Please see remarks for additional information
Name
Alternate Names
Anti-CD33 Monoclonal Antibody Calicheamicin
CDP 771
CDP-771
CDP771
CMA-676
hP67.6-calicheamicin
Mylotarg
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Targeted therapy
NSC Number
720568
716236
Primary Site
Leukemia
Histology
None
Remarks
June 16, 2020: The FDA extended the indication of gemtuzumab ozogamicin (MYLOTARGTM) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.
September 1, 2017: FDA approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
Monoclonal antibody. Gemtuzumab ozogamicin consists of a recombinant humanized anti-CD33 MAb conjugated to calicheamicin, a cytotoxic antibiotic. FDA approved for use on acute nonlymphocytic leukemia.
September 1, 2017: FDA approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
Monoclonal antibody. Gemtuzumab ozogamicin consists of a recombinant humanized anti-CD33 MAb conjugated to calicheamicin, a cytotoxic antibiotic. FDA approved for use on acute nonlymphocytic leukemia.
Coding
This drug should be coded
